LIMARIN® has a potent hepatoprotective effect by various
mechanisms facilitating physiology and metabolism of hepatocytes. Free radical
scavenging (antioxidant) action is via the glutathione system and superoxide dismutase.
LIMARIN stimulates synthesis of polymerase l, enhances ribosomal protein synthesis
and exerts a membrane stabilising effect.
LIMARIN® also reduces prostaglandin
LIMARIN® is known for its hepatoprotective action against
hepatic glutathione depletion induced by ethyl alcohol and paracetamol in animal
LIMARIN® reduces the turnover of membrane phospholipids and stabilises both extra and intracellular membranes inside hepatocytes.
also increases the phagocytic activity of the Kupffer cells, contributing to hepatoprotective
and regenerative effects.
absorbed to the extent of about 50% following an oral dose. The major ingredient,
Silibinin, is concentrated in the liver, reaches high concentration in the bile;
almost 30 times that in plasma; peak levels are attained 2-8 hrs. following oral
dose. Systemic half life is about 6.5 hrs. Main route of elimination is through
Drug Disease Interactions:
None reported so far.
- In patients with liver disorders, specially Hepatitis A.
Effective in preventing hepatic damage due to amanita poisoning.
Cirrhosis of liver, Chronic hepatitis, Alcoholic liver disease, Drug induced liver
damage and Fatty degeneration of the liver in diabetics
treatment in Alcoholic hepatitis, Chronic Active Hepatitis, Infective Hepatitis
A, Infective Hepatitis B, Cirrhosis of the liver and Toxic liver damage due to
drugs and toxins
may occur; mild laxative effect has been reported.
Special Safety Considerations:
Uneventful use in pregnancy has been recorded. However, large scale safety
studies have not been conducted.
Safety in pregnancy
has not been established.
Safety in lactation has
not been established. Use in pregnancy and lactation is not recommended.
Mild laxative effects.
Weigh risk benefit ratio before use in pregnancy and lactation